The 'three-parent baby' fertility doctor needs to stop marketing the procedure, FDA says
By Rachel Becker,
The Verge [cites Marcy Darnovsky]
| 08. 05. 2017
On Friday, FDA sent him a letter notifying him of his violations
The doctor who created a genetically modified “three-parent baby” has been reprimanded by the Food and Drug Administration for aggressively marketing the unapproved experimental procedure.
John Zhang, CEO of the New Hope Fertility Center in New York, famously combined the DNA of three people to help a mother who was a carrier for a genetic disease conceive an apparently healthy baby boy last year. Now, Zhang and his company are marketing the pricy procedure as the “first proven treatment for certain genetic disorders and a successful solution to age-related infertility.”
However, the FDA does not allow clinical research in people that would involve genetically modifying an embryo. And because Zhang’s technique and the one child it produced are both still in their infancy, we don’t know how well the treatment really works, or if it comes with any unforeseen consequences. On Friday, the FDA posted a letter to Zhang online, informing him that marketing the procedure is illegal, since the FDA hasn’t given him permission to...
Related Articles
By [cites CGS' Katie Hasson], KCBS Radio | 11.19.2025
This is Ask An Expert, where every weekday at 9:20am, KCBS Radio is giving you direct access to top experts in various fields. Today: Gene-editing technology allows scientists to work with DNA in unprecedented ways, but there are larger scientific...
By Alice Miranda Ollstein and Megan Messerly, Politico | 10.25.2025
By Ben Foldy, The Wall Street Journal | 10.21.2025
AnnaMaria Gallozzi and her husband wanted to have a second child last year. Because Gallozzi has advanced breast cancer, the couple sought out a surrogate who could carry their baby.
They used crowdfunding and took out a second mortgage on...
By Megan Molteni and Anil Oza, STAT | 10.07.2025
For two years, a panel of scientific experts, clinicians, and patient advocates had been hammering out ways to increase community engagement in National Institutes of Health-funded science. When they presented their road map to the NIH Director Jay Bhattacharya last...